Clinical trials: Mild-to-moderate Alzheimer's Disease Patients
Mild-moderate Alzheimer's Disease
Study of DHP1401 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil(DRAMA)
The objective of this study is to evaluate the efficacy and safety of DHP1401 in patients with mild-moderate Alzheimer's disease treated with donepezil
- Trial name
- NCT03055741
- Testing
- Donepezil, DHP1401
- Where
- 16 sites in South Korea
- Volunteers
- 180 people
- Sponsor
- Daehwa Pharmaceutical Co., Ltd.
Alzheimer Disease, Mild to Moderate
TMS Stimulation and Cognitive Training in Alzheimer Patients
The aim of this study is to examine if combined treatment with TMS and cognitive training (CoTra) for several weeks can produce a sustained improvement in cognitive and behavioral symptomatology of mild to moderate Alzheimer's…
- Trial name
- NCT01168245
- Testing
- NICE-System
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- Neuronix Ltd
Alzheimer's Disease
Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease
This study evaluated the effect of 6 or 12 infusions of different doses of octagam (intravenous immunoglobulin [IVIG]) 10% on the reduction of amyloid beta peptide (Aβ) in cerebral spinal fluid (CSF) and on the increase of Aβ in…
- Trial name
- NCT00812565
- Testing
- octagam 10%
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Octapharma
Alzheimer's Disease
Cognitive Changes in Alzheimer's Disease Patients Associated With or Without White Matter Changes After Rivastigmine
The purpose of this study is to evaluate and compare the changes of cognitive function (as measured by ADAS-Cog) in the two group of patients with Alzheimer's disease (AD) associated with and without white matter changes after…
- Trial name
- CAREER (NCT01380288)
- Testing
- rivastigmine patch
- Where
- 16 sites in South Korea
- Volunteers
- 300 people
- Sponsor
- Dong-A University
Alzheimer Disease
The Safety and Efficacy of Sodium Pentaborate Pentahydrate in Patients With Mild to Moderate Alzheimer's Disease
Alzheimer's disease (AD) is the leading cause of dementia, affecting millions worldwide. With its global prevalence steadily increasing, particularly in low- and middle-income countries, the demand for effective treatments has…
- Trial name
- NCT06840054
- Testing
- Sodium Pentaborate Pentahydrate
- Volunteers
- 30 people
- Sponsor
- Tabriz University of Medical Sciences
Alzheimer Disease
Implantable Vagus Nerve Stimulation Modulation of Coeruleus-Norepinephrine Network for Mild-Moderate AD Patients
A randomized controlled clinical study will be conducted in Xuanwu Hospital of Capital Medical University. This study initially explore the effect of selective vagus nerve(C fiber) stimulation on mild-to-moderate AD patients, in…
- Trial name
- NCT05575271
- Testing
- Vagus Nerve Stimulation Modulation of the Coeruleus-Norepinephrine Network
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Xuanwu Hospital, Beijing
Alzheimer's Disease
Safety and Efficacy of MEM 3454 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease
The purpose of this study is to determine in an 8-week treatment study if MEM 3454 is a safe and effective treatment for patients with mild to moderate Alzheimer's disease.
- Trial name
- NCT00454870
- Testing
- MEM 3454
- Where
- 7 sites in United States
- Volunteers
- 80 people
- Sponsor
- Memory Pharmaceuticals
Dementia Moderate, Dementia, Mild
Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease
Xanamem® is being developed as a potential treatment for symptomatic, early stages of Alzheimer's Disease (AD) and Major Depressive Disorder (MDD).
- Conditions
- Dementia Moderate, Dementia, Mild, Alzheimer Disease
- Trial name
- XanaMIA (NCT06125951)
- Testing
- Xanamem
- Where
- 34 sites in United States, Australia
- Volunteers
- 247 people
- Sponsor
- Actinogen Medical
Alzheimer's Disease
Effect of NeuroAD on Alzheimer Patients
Non-invasive stimulation of the brain using magnetic and cognitive stimulation by computer for the treatment of Alzheimer patients.
- Trial name
- NCT01825317
- Testing
- NeuroAD
- Where
- South Korea
- Volunteers
- 32 people
- Sponsor
- Neuronix Ltd
Alzheimer's Disease
MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease (0952-004)(COMPLETED)
MK0952 is a phosphodiesterase type IV (PDE4) inhibitor in development for improvement of cognitive impairment in mild-to-moderate Alzheimer's disease.
- Trial name
- NCT00362024
- Testing
- MK0952
- Volunteers
- 24 people
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer Disease
An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type
Objectives: The objective of this study will be to determine the safety, tolerability, drug blood levels, and efficacy of each of three doses of NS 2330 (Tesofensine) given once daily compared with placebo in patients with mild…
- Trial name
- NCT00153010
- Testing
- NS 2330 (Tesofensine)
- Where
- 87 sites in United States, Canada
- Volunteers
- 430 people
- Sponsor
- Boehringer Ingelheim
Alzheimer Disease
A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease
This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess safety, tolerability, pharmacokinetics, and efficacy of ONO-2020 in participants with mild to moderate Alzheimer's disease (AD).
- Trial name
- NCT06881836
- Testing
- ONO-2020
- Where
- 80 sites in United States, Japan
- Volunteers
- 260 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Alzheimer's Disease
European Study of HF0220 in Mild to Moderate Alzheimer's Disease Patients
The purpose of this Phase II study is to evaluate the safety and tolerability of HF 0220 in patients with Alzheimer's disease compared to placebo (inactive substance).
- Trial name
- NCT00357357
- Testing
- HF0220
- Where
- 10 sites in India, Sweden and 1 more
- Volunteers
- 40 people
- Sponsor
- Hunter-Fleming Ltd
Alzheimer's Disease, Central Nervous System Diseases
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
This study is being conducted to determine the safety and effect on cognitive function of the investigational medication, EVP-6124, in individuals with mild to moderate probable Alzheimer's disease.
- Conditions
- Alzheimer's Disease, Central Nervous System Diseases, Cognition
- Trial name
- NCT01073228
- Testing
- EVP-6124
- Where
- 54 sites in United States, Romania and 3 more
- Volunteers
- 409 people
- Sponsor
- FORUM Pharmaceuticals Inc
Alzheimer Disease
Efficacy and Safety of Donepezil and Sodium Oligomannate in Patients With Mild to Moderate Alzheimer's Disease
Alzheimer's disease (AD) is the main cause of dementia. At present, AD is incurable. Cholinesterase inhibitors, especially donepezil, are the first choice for mild and moderate AD.
- Trial name
- NCT05114499
- Testing
- Donepezil, GV-971
- Volunteers
- 150 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Alzheimer Disease
Study Evaluating Single Ascending Doses of AAB-001 Vaccine SAD Japanese Patients With Alzheimers Disease
Evaluate safety, tolerability, and pharmacokinetics of single doses of the investigational AAB-001 Vaccine in Japanese patients with Alzheimer's disease.
- Trial name
- NCT00397891
- Testing
- bapineuzumab
- Where
- 4 sites in Japan
- Volunteers
- 80 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Alzheimer's Disease
Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors
This is a multicenter study to evaluate the efficacy, safety and tolerability of Rivastigmine patch in patients with mild to moderate Alzheimer's disease switched from Cholinesterase Inhibitors.
- Trial name
- NCT01529619
- Testing
- Rivastigmine transdermal patch
- Where
- 11 sites in Japan
- Volunteers
- 52 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer Disease, Insomnia Disorder
Daridorexant to Treat Insomnia in Patients With Mild Cognitive Impairment and Mild to Moderate Alzheimer Disease
DARIDOR-ALZ is a phase IV clinical trial designed to evaluate both the efficacy and safety of daridorexant, a selective dual orexin receptor antagonist that blocks the actions of the orexin neuropeptides at both orexin-1 and…
- Conditions
- Alzheimer Disease, Insomnia Disorder, Sleep
- Trial name
- DARIDOR-ALZ (NCT05924425)
- Testing
- Daridorexant 50 mg, Polysomnography, Neuropsychological assessment
- Where
- France
- Volunteers
- 62 people
- Sponsor
- University Hospital, Montpellier
Alzheimer's
Clinical Efficacy of Ginkgo Biloba Extract in the Treatment of Alzheimer's Disease
This project explores Ginkgo biloba ester dispersible tablets influence on cognitive function in patients with mild-to-moderate elderly, to observe the effects of different intervention time on cognitive function, for alzheimer's…
- Trial name
- NCT03090516
- Testing
- Ginkgo biloba dispersible tablets, Donepezil, Ginkgo biloba dispersible tablets and Donepezil
- Where
- China
- Volunteers
- 240 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Alzheimer´s Disease
Safety Study of a Glycogen Synthase Kinase 3 (GSK3) Inhibitor in Patients With Alzheimer´s Disease
The purpose of this study is to evaluate if 4 escalating doses during 20 weeks of NP031112 are safe and tolerated in patients with Alzheimer´s disease.
- Trial name
- NCT00948259
- Testing
- NP031112
- Where
- 3 sites in Germany
- Volunteers
- 30 people
- Sponsor
- Noscira SA